Grouping and treatment
ESSENTIAL HYPERTENSION
Clinical trial: Elderly patients with essential hypertension were randomized into a control group (43 patients) and an observation group (43 patients) using the random number table method. All patients were treated with strict elution [discontinuation of previous oral antihypertensive drugs, at least 2 weeks for all types of drugs except diuretics for at least 4 weeks, and 2 weeks of placebo (a substance without pharmacological activity, provided by Novartis Pharmaceutical Co., Beijing, China) for elution treatment. Patients in the control group were given oral Amlodipine Besylate Tablets (specification: 5 mg/tablet, manufacturer: Beijing Novartis Pharmaceutical Co., Ltd.), 1 tablet/time/day; in the observation group, HMG-CoA reductase inhibitor (atorvastatin calcium; specification: 20 mg/tablet, manufacturer: Pfizer Pharmaceutical Co., Ltd.) was given on the basis of the control group, 20 mg/time, 1 time/day, taken orally at bedtime. Patients in both groups were treated with the drug for 12 weeks [Animal experiment: After 1 week of adaptive feeding, SHR rats were allocated into the model group (SHR rats without any treatment), HMG-CoA reductase inhibitor group (abbreviated as the HMG-CoA group, SHR rats were treated with atorvastatin calcium), AG490 group (SHR rats were given the JAK/STAT pathway inhibitors), and HMG-CoA + AG490 group (SHR rats were given atorvastatin calcium combined with the JAK/STAT pathway inhibitors) (n = 10). Ten WKY rats were selected as the normal group. Rats in the HMG-CoA and HMG-CoA + AG490 groups were given atorvastatin calcium 10 mg/kg/d in 1 mL distilled water by gavage, rats in the normal and model groups were given the same amount of distilled water by gavage, while rats in the AG490 and HMG-CoA + AG490 groups were given AG490 (5 mg/kg/d in 1 mL saline) by gavage daily for 12 weeks [